• Home
  • Latest
  • Coins2Day 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthBrainstorm Health

Brainstorm Health: Eclipse Glasses, FDA Approves Pfizer Leukemia Drug, MS Drug Prices

By
Clifton Leaf
Clifton Leaf
and
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
By
Clifton Leaf
Clifton Leaf
and
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
August 18, 2017, 12:00 PM ET

Good morning and happy Friday, readers! This is Sy.

You’ve almost certainly heard about the total solar eclipse set to occur on Monday, August 21. The rare event will be visible in certain regions within more than a dozen states.

But, even with cosmic events, it’s important to put safety first. And when it comes to staring into the sun, that means protecting your eyes with special gear.

Unfortunately, some would-be viewers could have a bit of a problem with that. There have been reports of unauthorized eyewear that have led to recalls and suggestions from county officials in Richland, South Carolina (one of the areas where the eclipse will be visible in its totality) to seek “other options” than the free glasses made available if people feel uncomfortable. There have also been counterfeit pairs sold on Amazon (for which the company has offered refunds).

The American Astronomical Society (AAS) has an approved list of vendors for solar filters.

Read on for the day’s news, and enjoy your weekend!

Sy Mukherjee
@the_sy_guy
[email protected]

DIGITAL HEALTH

IBM to team up with JDRF on type 1 diabetes.  IBM and JDRF, an outfit focused on funding type 1 diabetes research, are teaming up to analyze the factors that may lead to that form of diabetes. The collaboration will involve creating machine learning methods which can analyze mountains of existing type 1 diabetes research in order to figure out risk factors and, hopefully, effective prevention measures.

INDICATIONS

FDA clears Pfizer drug for rare, fast-spreading cancer. The Food and Drug Administration (FDA) has approved Pfizer's Besponsa, a drug to treat a rare and vicious form of leukemia that can quickly kill patients. Besponsa is approved for adults with hard-to-treat or recurring forms of B-cell precursor acute lymphoblastic leukemia (ALL), which nearly 6,000 Americans are diagnosed with each year. (Coins2Day)

House Democrats push for explanation of high MS drug prices. House Democratic lawmakers have launched an investigation into pricing for multiple sclerosis drugs. Seven companies, including pharmaceutical giants like Biogen, Sanofi, Novartis, and Roche, have received letters from the House Government Oversight Committee requesting information on their pricing strategies. (Coins2Day)

REQUIRED READING

The Most Successful CEO of His Generation Steps Down, by Shawn Tully

If You Bought Google At Its IPO Price, Here's How Much Richer You'd Be, by Lucinda Shen

Among Startups, Microsoft and Google Are Giving AWS a Run for Its Money, by Barb Darrow

World Stocks Tumble As Market Hopes in Trump's Reform Agenda Fade, by Coins2Day Editors and Reuters

Produced by Sy Mukherjee
@the_sy_guy
[email protected]

Find past coverage. Sign up for other  Coins2Day  newsletters.
About the Authors
By Clifton Leaf
See full bioRight Arrow Button Icon
By Sy Mukherjee
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.


Most Popular

placeholder alt text
North America
'I meant what I said in Davos': Carney says he really is planning a Canada split with the U.S. along with 12 new trade deals
By Rob Gillies and The Associated PressJanuary 28, 2026
2 days ago
placeholder alt text
Politics
The American taxpayer spent nearly half a billion dollars deploying federal troops to U.S. cities in 2025, CBO finds
By Nick LichtenbergJanuary 28, 2026
1 day ago
placeholder alt text
C-Suite
Jeff Bezos capped his Amazon salary at $80,000: ‘How could I possibly need more incentive?’
By Sydney LakeJanuary 28, 2026
2 days ago
placeholder alt text
C-Suite
Coins2Day 500 CEOs are no longer giving employees an A for effort. Now they want proof of impact
By Claire ZillmanJanuary 28, 2026
2 days ago
placeholder alt text
Investing
Jerome Powell got a direct question about the U.S. ‘losing credibility’ and the soaring price of gold and silver. He punted
By Eva RoytburgJanuary 29, 2026
18 hours ago
placeholder alt text
Personal Finance
Current price of silver as of Thursday, January 29, 2026
By Joseph HostetlerJanuary 29, 2026
18 hours ago

Latest in Health

C-SuiteCoins2Day 500: Titans and Disruptors of Industry
Pfizer CEO says he used ‘emotional blackmail’ to get employees to achieve impossible goals during COVID-19
By Eva RoytburgJanuary 29, 2026
8 hours ago
man
HealthHealth
Life is actually getting better—and longer—for Americans, despite everything you read in the news
By Mike Stobbe and The Associated PressJanuary 29, 2026
12 hours ago
A pile of different-sized mattresses.
Healthmattresses
A Guide to All Mattress Dimensions: How to Choose the Right Size Bed
By Jessica RendallJanuary 29, 2026
13 hours ago
brooks
CommentaryInsurance
John Hancock CEO: We all have a role in driving better health outcomes for Americans
By Brooks TingleJanuary 29, 2026
18 hours ago
A middle-aged man and woman sit in a bedroom while looking despondent
Healthfinances
75 years ago, the midlife crisis was a global problem. Now it’s an American affliction, and it’s ‘not just about buying a sports car’
By Tristan BoveJanuary 29, 2026
19 hours ago
Healthoutdoor and sporting goods
The 4 Best Cold Plunge Tubs of 2026: Reviewed by Testers and Experts
By Christina SnyderJanuary 28, 2026
1 day ago